- Email: [email protected]
5434131 Chimeric CTLA4 receptor and methods for its use
PATENT ABSTRACTS
PCT No. PCT/US90/07496 Sec. 371 Date Aug. 21, 1992 Sec. 102(e) Date Aug. 21, 1992 PCT Filed Dec. 18, 1990 PCT Pub. No. WO91/09135 PCT Pub. Date Jun. 27, 1991. Disclosed is a process for the preparation and use of gynecological tumor diagnostic and antitumor reagents. The process involves the pre-treatment of a patient with a viral oncolysate and the establishment of stable B cell human hybridomas capable of producing human monocional antibodies reactive with cell surface epitopes of human gynecological tumors. At least one such surface epitope is described as is the association constant of the antibody for certain gynecological tumor cells. Also disclosed are methods for utilizing the monoclonal antibodies of the invention in diagnoses and treatment of gynecological malignancies. In addition, two particularly useful gynecological hybridoma lines are disclosed which were derived from the process of the invention. 5434131 CHIMERIC CTLA4 RECEPTOR AND METHODS FOR ITS USE Linsley Peter S; Ledbetter Jeffrey A; Damle Nitin K; Brady William Seattle, WA, UNITED STATES assigned to Bristol Myers Squibb Co The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
5434247 PEPTIDES FOR INDUCING MONOCYTE CYTOTOXICITY IN DIAGNOSTICS Jones C Michael Houston, TX, UNITED STATES assigned to Board of Regents The University of Texas System
571
The present disclosure relates to a new lymphokine molecule termed Monocyte Cytotoxicity Inducing Factor (MCF), to MCF peptides. The disclosure further relates to the development of novel Sezary cell hybridomas which secrete MCF, to the purification of MCF and its constituent polypeptides and to the identification of small peptides with MCF activity. Sezary OKT4+ lymphocytes were fused to CEM.8azar.C, an HGPRTase lacking clone of CEM, to generate hybrid cells, certain of which produced soluble mediators of human monocyte cytotoxicity. A single sezary hybrid clone, FtF3, produced a novel monocyte cytotoxicity inducing factor found to be distinct from IFN gamma and IFN alpha. MCF, purified by dye ligand and ion-exchange chromatography, comprises two polypeptides of 29 and 14.7kD (P29 and P14.7) which can be further purified by preparative SDS/PAGE and hydrophobic chromatography, respectively. Amino acid composition analyses and immunoblotting of two-dimensional gels indicate that these are distinct but possibly related polypeptides. N-terminal analysis of P29 reveals it to be a previously undescribed cytokine mediator of monocyte function. A peptide having the sequence Gly Ala Ala Val Leu Glu Asp Set Gin, corresponding to the native N-terminal sequence of P29, also exhibits MCF activity equivalent to that of the intact 29kD protein.
5435999 PROLIFERATIVE ACTION OF LEUKAEMIA INHIBITORY FACTOR ON SATELLITE CELLS Austin Lawrence Mount Waverley, AUSTRALIA assigned to Monash University PCT No. PCT/AU90/00556 Sec. 371 Date Aug. 12, 1991 Sec. 102(e)Date Aug. 12, 1991 PCT Filed Nov. 20, 1990 PCT Pub. No. WO91/07992 PCT Pub. Date Jun. 13, 1991. The present
PCT No. PCT/US90/07496 Sec. 371 Date Aug. 21, 1992 Sec. 102(e) Date Aug. 21, 1992 PCT Filed Dec. 18, 1990 PCT Pub. No. WO91/09135 PCT Pub. Date Jun. 27, 1991. Disclosed is a process for the preparation and use of gynecological tumor diagnostic and antitumor reagents. The process involves the pre-treatment of a patient with a viral oncolysate and the establishment of stable B cell human hybridomas capable of producing human monocional antibodies reactive with cell surface epitopes of human gynecological tumors. At least one such surface epitope is described as is the association constant of the antibody for certain gynecological tumor cells. Also disclosed are methods for utilizing the monoclonal antibodies of the invention in diagnoses and treatment of gynecological malignancies. In addition, two particularly useful gynecological hybridoma lines are disclosed which were derived from the process of the invention. 5434131 CHIMERIC CTLA4 RECEPTOR AND METHODS FOR ITS USE Linsley Peter S; Ledbetter Jeffrey A; Damle Nitin K; Brady William Seattle, WA, UNITED STATES assigned to Bristol Myers Squibb Co The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid CTLA4 fusion proteins, and for using the soluble fusion proteins, fragments and derivatives thereof, including monoclonal antibodies reactive with B7 and CTLA4, to regulate T cell interactions and immune responses mediated by such interactions.
5434247 PEPTIDES FOR INDUCING MONOCYTE CYTOTOXICITY IN DIAGNOSTICS Jones C Michael Houston, TX, UNITED STATES assigned to Board of Regents The University of Texas System
571
The present disclosure relates to a new lymphokine molecule termed Monocyte Cytotoxicity Inducing Factor (MCF), to MCF peptides. The disclosure further relates to the development of novel Sezary cell hybridomas which secrete MCF, to the purification of MCF and its constituent polypeptides and to the identification of small peptides with MCF activity. Sezary OKT4+ lymphocytes were fused to CEM.8azar.C, an HGPRTase lacking clone of CEM, to generate hybrid cells, certain of which produced soluble mediators of human monocyte cytotoxicity. A single sezary hybrid clone, FtF3, produced a novel monocyte cytotoxicity inducing factor found to be distinct from IFN gamma and IFN alpha. MCF, purified by dye ligand and ion-exchange chromatography, comprises two polypeptides of 29 and 14.7kD (P29 and P14.7) which can be further purified by preparative SDS/PAGE and hydrophobic chromatography, respectively. Amino acid composition analyses and immunoblotting of two-dimensional gels indicate that these are distinct but possibly related polypeptides. N-terminal analysis of P29 reveals it to be a previously undescribed cytokine mediator of monocyte function. A peptide having the sequence Gly Ala Ala Val Leu Glu Asp Set Gin, corresponding to the native N-terminal sequence of P29, also exhibits MCF activity equivalent to that of the intact 29kD protein.
5435999 PROLIFERATIVE ACTION OF LEUKAEMIA INHIBITORY FACTOR ON SATELLITE CELLS Austin Lawrence Mount Waverley, AUSTRALIA assigned to Monash University PCT No. PCT/AU90/00556 Sec. 371 Date Aug. 12, 1991 Sec. 102(e)Date Aug. 12, 1991 PCT Filed Nov. 20, 1990 PCT Pub. No. WO91/07992 PCT Pub. Date Jun. 13, 1991. The present